Netherlands· NL-0ae13fc428f0
Kengrexal 50 mg poeder voor concentraat voor oplossing voor injectie / infusie
A cangrelor product containing cangrelor tetranatrium, registered in Netherlands by Chiesi Farmaceutici S.p.A.. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Cangrelor is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AC25 (cangrelor), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Cangrelor · ATC B01AC25
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CANGRELOR TETRANATRIUM
- Manufacturer
- Chiesi Farmaceutici S.p.A.
- Country
- Netherlands (NL)
- ATC code
- B01AC25
- ATC class
- Cangrelor
- Defined daily dose
- 50 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/994
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
135 interactions on record for cangrelor.
Graded by severity as the source publishes them — 65 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cangrelor · interactions on record
135 records
- 65 severe
- 70 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cangrelor in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceKENGREXAL 50 mg, poudre pour solution à diluer pour solution injectable/pour perfusionCHIESI FARMACEUTICI
- United KingdomKengrexal 50mg powder for concentrate for solution for injection / infusion vialsChiesi Ltd
- United StatesCangrelorGland Pharma Limited
- CzechiaKENGREXALChiesi Farmaceutici S.p.A., Parma
- SpainKENGREXAL 50 MG POLVO PARA CONCENTRADO PARA SOLUCION INYECTABLE Y PARA PERFUSIONChiesi Farmaceutici S.P.A.
- CanadaKENGREXALCHIESI FARMACEUTICI S.P.A.
- IcelandKengrexalChiesi Farmaceutici S.p.A.*
- PolandKengrexalChiesi Farmaceutici S.p.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae2ead79-19e7-439c-8fa1-4b7a4bb8574c GET /v1/drugs/ae2ead79-19e7-439c-8fa1-4b7a4bb8574c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kengrexal-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Cangrelor",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp114709",
"excipients": [
"MANNITOL (D-) (E 421)",
"NATRIUMHYDROXIDE (E 524)",
"SORBITOL (E 420)",
"STIKSTOF (HEAD SPACE) (E 941)"
],
"substances": [
"CANGRELOR TETRANATRIUM"
],
"leaflet_url": null,
"authorised_at": "2015/03/23",
"procedure_number": "EMEA/H/C/003773",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/994",
"additional_monitoring": "N"
}See everything about cangrelor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.